findmyKOL
Clinical trialNCT02896335RecruitingPhase 2Interventional

Palbociclib and Pembrolizumab In Central Nervous System Metastases

SponsorMassachusetts General HospitalEnrollment45Metastatic Malignant Neoplasm to BrainProgressive Brain MetastasesRecurrent Brain Metastases
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

    Eudocia Lee, MD
    Not, yet, recruiting
  • Massachusetts General Hospital

    Boston, Massachusetts, United States

    Priscilla Brastianos, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
2 Feb 2017
Primary completion
1 Sept 2026
Completion
1 Sept 2027
Last update posted
12 Mar 2026
Registered enrollment
45
Registry id
NCT02896335
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.